Search ACAD
ACADIA PHARMACEUTICALS INC
Nasdaq · CIK 1070494
Last close19.95
Daily change+0.06 (0.30%)
10 Years gain-35.04%
Dividends TTM0
Dividend yield0.00%
Fundamental Analysis
ACAD · STANDARD
SIC 2834 · Pharmaceutical Preparations · Fiscal year end 1231
Fundamental
70.4Momentum
44.0Acceleration
44.0Confidence
89.0Annual Revenue17
Quarterly Revenue74
Annual CFO14
Balance SheetAvailable
RankingEligible
Score Breakdown
Growth20.0 / 25
Quality7.0 / 25
Capital Efficiency20.0 / 20
Balance Sheet15.0 / 15
Shareholder Economics4.9 / 10
Forward Indicators0.0 / 5
Signals
Gross margin expansionGross margin improved by 0.0019 percentage points.
Net debt reductionNet debt declined versus the comparison period.
Warnings
Receivables anomaly · MEDIUMAccounts receivable growth is materially above revenue growth.
Key Metrics
Revenue Growth TTM18.75%OK
Revenue CAGR 3Y27.48%OK
Gross Margin91.47%OK
Operating Margin9.06%OK
FCF Marginn/aMISSING
FCF Growthn/aINSUFFICIENT_HISTORY
ROIC30.37%OK
Incremental Operating Margin 3Yn/aNOT_MEANINGFUL
Net Debt / CFOn/aNOT_MEANINGFUL
Diluted Share Growth 1Y3.09%OK
SBC / Revenuen/aMISSING
SBC / FCFn/aNOT_MEANINGFUL
Financial History
| Period | Revenue | Gross Profit | Operating Income | CFO | FCF | Gross Margin | Op Margin | FCF Margin | ROIC | Shares |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025 FY Dec 31, 2025 | $1.07B | $982.51M | $104.81M | $109.84M | $105.15M | 91.69% | 9.78% | 9.81% | 35.44% | 169.92M |
| 2025 FY Dec 31, 2024 | $957.80M | $875.96M | $230.79M | $157.72M | $157.20M | 91.46% | 24.1% | 16.41% | n/a | 166.36M |
| 2025 FY Dec 31, 2023 | $726.44M | $684.80M | -$73.38M | $16.70M | $16.65M | 94.27% | -10.1% | 2.29% | n/a | 163.82M |
| 2024 FY Dec 31, 2022 | $517.24M | $507.07M | -$223.60M | -$114.04M | -$114.04M | 98.03% | -43.23% | -22.05% | -9,351.02% | 161.68M |
| 2023 FY Dec 31, 2021 | $484.15M | $465.00M | -$170.44M | -$125.66M | -$126.78M | 96.05% | -35.2% | -26.19% | -1,767.13% | 160,493 |
Formula Trace
| Metric | Value | Formula | Status | Source |
|---|---|---|---|---|
| Revenue TTM | $1.12B | sum latest 4 fiscal quarters Revenue | OK | 0001193125-26-333243, 0001193125-25-267453 |
| Revenue Growth TTM | 18.75% | Revenue_TTM / Revenue_TTM_1Y_ago - 1 | OK | 0001193125-26-333243, 0001193125-25-267453 |
| Revenue CAGR 3Y | 27.48% | (Revenue_current / Revenue_3Y_ago)^(1/3) - 1 | OK | 0001193125-26-072519 |
| Revenue CAGR 5Y | 19.39% | (Revenue_current / Revenue_5Y_ago)^(1/5) - 1 | OK | 0001193125-26-072519 |
| Gross Profit CAGR 3Y | 24.67% | (GrossProfit_current / GrossProfit_3Y_ago)^(1/3) - 1 | OK | 0001193125-26-072519 |
| Operating Income Growth | 4.94% | OperatingIncome_current / OperatingIncome_prior_year - 1 | OK | 0001193125-26-333243, 0001193125-25-267453 |
| FCF Growth | n/a | FCF_current / FCF_prior_year - 1 | INSUFFICIENT_HISTORY | derived |
| Revenue Growth Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Profit Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Operating Income Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| FCF Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Margin | 91.47% | Gross Profit / Revenue | OK | 0001193125-26-333243, 0001193125-25-267453 |
| Operating Margin | 9.06% | Operating Income / Revenue | OK | 0001193125-26-333243, 0001193125-25-267453 |
| ROIC | 30.37% | NOPAT / Average Invested Capital | OK | 0001193125-26-333243, 0001193125-25-267453 |
| Net Debt / CFO | n/a | Net Debt / CFO | NOT_MEANINGFUL | 0001193125-26-333243 |
| Current Ratio | 3.39x | Current Assets / Current Liabilities | OK | derived |
| Revenue per Diluted Share | $6.48 | Revenue / Diluted Shares | OK | 0001193125-26-333243, 0001193125-25-267453 |
| SBC / FCF | n/a | SBC / FCF | NOT_MEANINGFUL | derived |